"This is long-term follow-up data that confirms what we expected," Brown said. "We have been waiting for years to determine if the results are short-lived or if we see it years later, and now we know that we see the survival benefit 10 years out."
"Doctors are used to giving IV chemotherapy, so this is a new skill set in terms of giving the drugs," she said. "It comes with different equipment and patient instructions and side effects. As individual physicians and centers become more comfortable and confident with learning how to manage the side effects, its use will increase."
Dr. Elizabeth Poynor, a gynecologic oncologist at New York City's Lenox Hill Hospital, agreed. "The toxicity and intensity is greater than with IV therapy, so some people can't tolerate it," she said. "But for those who do, survival is clearly benefited."
"It's a tradeoff," Poynor said. "There are more side effects, but there are also survival benefits. You don't know how you will tolerate it until you try -- and if it's not for you, you can back off."
Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.
Learn more about treatment for ovarian cancer at the U.S. National Cancer Institute.
SOURCE: Elizabeth Poynor, M.D., gynecologic oncologist, Lenox Hill Hospital, New York City; Jubilee Brown, M.D., associate professor, department of gynecologic oncology, division of surgery, University of Texas MD Anderson Cancer Center, Houston; Devansu Tewari, M.D., director, gynecologic oncology, Southern California Permanente Medical Group, Orange County; March 9, 2013,
All rights reserved